Tucatinib-d6
Tucatinib-d6 (Irbinitinib-d6) is deuterium labeled Tucatinib. Tucatinib (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C26H18D6N8O2
- Masse moléculaire:486.56
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform EGFR
More
Activité biologique
Description
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled CAS 937263-43-9
-
Masse moléculaire 486.56
-
Formule C26H18D6N8O2
-
SMILES
[2H]C(C1(C([2H])([2H])[2H])N=C(NC2=CC3=C(NC4=CC=C(OC5=CC6=NC=NN6C=C5)C(C)=C4)N=CN=C3C=C2)OC1)([2H])[2H]
-
Synonyms
Irbinitinib-d6; ARRY-380-d6; ONT-380-d6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Pureté et documentation
Références
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[4]. Moulder-Thompson S, et al. Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clin Cancer Res. 2017 Jan 4. pii: clincanres.1496.2016. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)